Americans are going to get a little healthier.

President Trump cut deals with the drugmakers Eli Lilly and Novo Nordisk to increase access to obesity drugs in a major benefit to American public health.

The agreements are a win-win-win — good for consumers, good for the companies and good for Trump.

One of the most irrational superstitions of our time is that Big Pharma, which has long been routinely delivering near-miraculous therapeutics to extend and improve our lives, is a public enemy. Its latest breakthrough is a class of so-called GLP-1 drugs that make it easier to lose weight, and to avoid associated serious health problems, from Type 2 diabetes to heart disease.

The basic dynamic of the Trump deals is that the companies will, through lower prices, expand their market share, thu

See Full Page